Clinical Trials

Find trials by condition, location & phase

Drug Monographs

Browse drug monographs and information

Explore organizations and their profiles

Latest updates on trials and healthcare

Approved products by global authorities

AI-Powered Research

Discover powerful insights with advanced AI analysis tools for clinical trials.

Premium Access

Get unlimited access to our comprehensive pharmaceutical database and analytics.

Luye Pharma Group Ltd.

🇨🇳China

Country: 🇨🇳China

Ownership: Public

Established: 2014-04-28

Employees: 5.2K

Market Cap: -

Website: http://www.luye.cn

Clinical Trials

A Phase 1, MAD Study to Evaluate the Safety, Tolerability and Pharmacokinetics of LY03017

Phase 1

Not yet recruiting

Conditions: Hallucinations and Delusions Associated With Alzheimer's Disease Psychosis
Hallucinations and Delusions Associated With Parkinson Disease Psychosis
Negative Symptoms of Schizophrenia

Interventions: Drug: LY03017
Drug: LY03017-Placebo

First Posted Date: 2025-05-20

Last Posted Date: 2025-05-20

Lead Sponsor: Luye Pharma Group Ltd.

Target Recruit Count: 40

Registration Number: NCT06980207

Locations: 🇨🇳
Shanghai Mental Health Center, Shanghai, China

Effect of Food and Age on the Pharmacokinetics of LY03017

Phase 1

Not yet recruiting

Conditions: Alzheimer's Disease Psychosis
Parkinson Disease Psychosis
Negative Symptoms of Schizophrenia

Interventions: Drug: LY03017

First Posted Date: 2025-01-27

Last Posted Date: 2025-01-27

Lead Sponsor: Luye Pharma Group Ltd.

Target Recruit Count: 26

Registration Number: NCT06793995

Locations: 🇨🇳
Shanghai Mental Health Center, Shanghai, China

Safety and Efficacy of LPM3770164 Sustained-release Tablets in Patients With Tardive Dyskinesia

Phase 1

Recruiting

Conditions: Tardive Dyskinesia (TD)

Interventions: Drug: LPM3770164 sustained release tablet 5 mg
Drug: LPM3770164 sustained release tablet 10 mg
Drug: LPM3770164 sustained release tablet 20 mg
Drug: LPM3770164 sustained release tablet simulant

First Posted Date: 2024-12-12

Last Posted Date: 2025-01-22

Lead Sponsor: Luye Pharma Group Ltd.

Target Recruit Count: 120

Registration Number: NCT06731868

Locations: 🇨🇳
Shanghai Mental Health Center, Shanghai, China

A Study Assessing the Safety and Tolerability of LY03020 in Chinese Healthy Subjects

Phase 1

Completed

Conditions: Schizophrenia
Alzheimer's Disease Psychosis

Interventions: Drug: LY03020
Drug: Placebo

First Posted Date: 2024-08-16

Last Posted Date: 2025-05-29

Lead Sponsor: Luye Pharma Group Ltd.

Target Recruit Count: 66

Registration Number: NCT06556966

Locations: 🇨🇳
Beijing AnDing Hospital Capital Medical University, Beijing, China

Lurbinectedin or in Combination with Irinotecan Versus Topotecan in Patients with Relapsed SCLC

Phase 3

Recruiting

Conditions: Relapsed Small Cell Lung Cancer

Interventions: Drug: Irinotecan
Drug: Lurbinectedin
Drug: Topotecan

First Posted Date: 2024-07-11

Last Posted Date: 2024-12-12

Lead Sponsor: Luye Pharma Group Ltd.

Target Recruit Count: 180

Registration Number: NCT06496048

Locations: 🇨🇳
Jilin Provincial Tumor Hospital, Jilin, China

Effect of Food on the Pharmacokinetics of LPM3770164 Sustained-release Tablets

Phase 1

Completed

Conditions: Huntington Disease
Tardive Dyskinesia

Interventions: Drug: LPM3770164 sustained release tablet

First Posted Date: 2024-06-25

Last Posted Date: 2024-12-12

Lead Sponsor: Luye Pharma Group Ltd.

Target Recruit Count: 16

Registration Number: NCT06474650

Locations: 🇨🇳
Shanghai Mental Health Center, Shanghai, China

Phase II Clinical Trial to Evaluate the Efficacy and Safety of LPM3480392 Injection for Moderate to Severe Pain After Orthopedic Surgery

Phase 2

Recruiting

Conditions: Pain, Postoperative

Interventions: Drug: Placebo
Drug: morphine hydrochloride injection
Drug: LPM3480392 Injection

First Posted Date: 2024-06-21

Last Posted Date: 2024-06-21

Lead Sponsor: Luye Pharma Group Ltd.

Target Recruit Count: 150

Registration Number: NCT06467409

Locations: 🇨🇳
Union Hospital Affiliated to Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China

To Evaluate the Long-term Efficacy and Safety of Toludevenlafaxine Hydrochloride Sustained-release Tablets

Phase 4

Not yet recruiting

Conditions: Major Depressive Disorder

Interventions: Drug: placebo
Drug: Toludesvenlafaxine Hydrochloride Sustained-release Tablets

First Posted Date: 2024-05-23

Last Posted Date: 2024-05-23

Lead Sponsor: Luye Pharma Group Ltd.

Target Recruit Count: 736

Registration Number: NCT06426485

A Phase 1, SAD Study to Evaluate the Safety and Tolerability of LY03017

Phase 1

Not yet recruiting

Conditions: Hallucinations and Delusions Associated With Alzheimer's Disease Psychosis
Hallucinations and Delusions Associated With Parkinson Disease Psychosis
Negative Symptoms of Schizophrenia

Interventions: Drug: LY03017-Placebo
Drug: LY03017

First Posted Date: 2024-04-29

Last Posted Date: 2024-04-29

Lead Sponsor: Luye Pharma Group Ltd.

Target Recruit Count: 60

Registration Number: NCT06388551

Locations: 🇨🇳
Shanghai Mental Health Center, Shanghai, China

First-in-Human Study of LPM6690176 in Patients With Advanced Solid Tumors.

Phase 1

Recruiting

Conditions: Advanced Solid Tumor

Interventions: Drug: LPM6690176

First Posted Date: 2024-02-05

Last Posted Date: 2024-03-15

Lead Sponsor: Luye Pharma Group Ltd.

Target Recruit Count: 102

Registration Number: NCT06240546

Locations: 🇨🇳
Beijing Cancer Hospital, Beijing, China

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy